Global Oncology Academy
The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.
For more information about GOA, visit www.globaloncologyacademy.org.
1-15 of 439
A Look at WCLC 2026: Pivotal Trials and Emerging Directions
Project Oncology®A Look at WCLC 2026: Pivotal Trials and Emerging Directions
Triparna Sen, PhD
Making the Most of WCLC 2026: A Guide for Early-Career Professionals
Project Oncology®Making the Most of WCLC 2026: A Guide for Early-Career Professionals
Triparna Sen, PhD
Closing the Colonoscopy Follow-Up Gap: Insights from a JNCCN Study
Clinician's RoundtableClosing the Colonoscopy Follow-Up Gap: Insights from a JNCCN Study
Peter Buch, MD, FACG, AGAF, FACP
Mallik Greene, PhD
Jordan Karlitz, MD
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP
Virginia Kaklamani, MD, DSc
Closing the Evidence Gap in Metastasis-Directed Therapy for mBC
Project Oncology®Closing the Evidence Gap in Metastasis-Directed Therapy for mBC
Lajos Pusztai, MD, DPhil
Is There a Role for Primary Tumor Surgery in Metastatic Breast Cancer?
Project Oncology®Is There a Role for Primary Tumor Surgery in Metastatic Breast Cancer?
Lajos Pusztai, MD, DPhil
- advertisement
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
MinuteCE®The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Komal Jhaveri, MD, FACP
Virginia Kaklamani, MD, DSc
Komal Jhaveri, MD, FACP
Virginia Kaklamani, MD, DSc
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Virginia Kaklamani, MD, DSc
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Project Oncology®Emerging Endpoints for Evaluating Treatment Benefit in pLGG
Shelina Ramnarine, PhD
Mohamed Abdelbaki, MD
Exploring Combination Treatment in ER+/HER2- Breast Cancer
Project Oncology®Exploring Combination Treatment in ER+/HER2- Breast Cancer
Charles Turck, PharmD, BCPS, BCCCP
Wassim Mchayleh, MD, MBA, FACP
- advertisement
What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
Project Oncology®What’s Behind the Toxicity? Key Clues in Urothelial Carcinoma
Petros Grivas, MD, PhD
Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Project Oncology®Monitoring Toxicities During Advanced Urothelial Carcinoma Treatment
Petros Grivas, MD, PhD
Supporting Patients Throughout Urothelial Carcinoma Treatment
Project Oncology®Supporting Patients Throughout Urothelial Carcinoma Treatment
Petros Grivas, MD, PhD
